The Valley Desk

NCT04566393 · Expanded access

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Overall registry status Available

Conditions BRAF Gene Mutation, Bladder Cancer, Cholangiocarcinoma, Colorectal Cancer, ERK Mutation, Esophageal Cancer, Gastric Cancer, Glioblastoma, HRAS Gene Mutation, Head and Neck Cancer, Hepatocellular Carcinoma, KRAS Activating Mutation, MAPK Gene Mutation, MEK Mutation, Melanoma, NRAS Gene Mutation, Non Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Small Bowel Cancer, Thyroid Cancer

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov